According to recent findings from The Hill, the number of GLP-1 prescriptions issued to children has experienced an unprecedented increase, rising by more than 30,000 percent since 2019. This dramatic surge highlights a significant shift in pediatric treatment approaches for conditions that these medications target.
AstraZeneca's tozorakimab significantly reduces COPD symptoms in smokers and ex-smokers, earning FDA priority review as the first biologic treatment for the condition.
New research reveals that erratic meal times on weekends significantly increase cardiovascular risk, particularly for men who delay breakfast until noon.
New legislation and expired subsidies are pushing millions uninsured, triggering a ripple effect of hospital closures, overcrowded ERs, and higher premiums for…
I lost weight on Ozempic as an adult, but seeing this spike for kids is honestly quite alarming to me.
We need more data before this becomes the standard of care for children. What about impacts on developing bodies?
Pharma companies are surely thrilled with these numbers. Just another reminder of how profitable the obesity crisis has become.
Thirty thousand percent sounds insane. Are they prescribing these to ten-year-olds or just treating severe adolescent obesity cases?
My doctor says these are still off-label for most kids. I hope pediatricians are monitoring long-term effects closely.